Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01057459 · ClinicalTrials.gov registry record

DNA Analysis in Predicting Response to Antibody Therapy in Patients With Follicular Lymphoma Treated on Clinical Trials CALGB-50402 or CALGB-50701

A clinical trial of Lymphoma, sponsored by Alliance for Clinical Trials in Oncology.

Completed
Registry status
78
Enrollment target
1
Study location

NCT01057459: Completed study of Lymphoma, sponsored by Alliance for Clinical Trials in Oncology.

NCT01057459 is a study of Lymphoma that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 78 participants, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01057459, a study of Lymphoma, has completed, sponsored by Alliance for Clinical Trials in Oncology.

COMPLETED
Registry status
78 participants
Enrollment target
1
Study location

Study Summary

This research trial studies deoxyribonucleic acid (DNA) analysis in predicting response to antibody therapy in patients with follicular lymphoma treated on clinical trials Cancer and Leukemia Group B (CALGB)-50402 or CALGB-50701. Studying samples of blood from patients with follicular lymphoma in the laboratory may help doctors predict how well patients will respond to treatment.

Conditions Studied

Lymphoma

Interventions

  • OTHER laboratory biomarker analysis

Study Locations (1)

New York

  • Memorial Sloan-Kettering Cancer Center - New York

Trial Details

FieldValue
Enrollment Target 78 participants
Start Date 2010-02
Est. Completion 2014-06-23
Alliance for Clinical Trials in Oncology

446 total trials

What the finished NCT01057459 record still lists

NCT01057459 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 78 participants, a relatively small participant target, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (84% lower).

The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which laboratory biomarker analysis is the first listed.

NCT01057459 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT01057459 about?

NCT01057459 is a clinical study titled "DNA Analysis in Predicting Response to Antibody Therapy in Patients With Follicular Lymphoma Treated on Clinical Trials CALGB-50402 or CALGB-50701". This research trial studies deoxyribonucleic acid (DNA) analysis in predicting response to antibody therapy in patients with follicular lymphoma treated on clinical trials Cancer and Leukemia Group B (CALGB)-50402 or CALGB-50701. Studying samples of blood from patients with follicular lymphoma in th...

What is the current status of trial NCT01057459?

This trial is currently completed. The enrollment target is 78 participants. The study started on 2010-02. Estimated completion is 2014-06-23.

What conditions does trial NCT01057459 study?

This clinical trial studies the following conditions: Lymphoma.

What interventions are being tested in trial NCT01057459?

The interventions under investigation include: laboratory biomarker analysis (OTHER).

Who is sponsoring clinical trial NCT01057459?

This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01057459 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01057459's enrollment target sits among peer trials

78 106th of 299 higher than 191 of 299 other Lymphoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02397668 · 78 participants · NA

    CorMatrix Cor TRICUSPID ECM Valve Replacement Study

  • NCT03321656 · 78 participants · Phase 2

    Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile

  • NCT03687814 · 78 participants · NA

    Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation

  • NCT04018872 · 78 participants · Phase 2

    Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT01057459, the US trial registry maintained by the National Library of Medicine. NCT01057459 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.